Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 14/20 | 0.58 |
| ▸ | MMP1 | P03956 | 10/20 | 0.58 |
| ▸ | MMP12 | P39900 | 2/20 | 0.58 |
| ▸ | MMP13 | P45452 | 2/20 | 0.58 |
| ▸ | MMP9 | P14780 | 11/20 | 0.46 |
| ▸ | MMP8 | P22894 | 8/20 | 0.46 |
| ▸ | MMP3 | P08254 | 6/20 | 0.46 |
| ▸ | MMP7 | P09237 | 4/20 | 0.46 |
| ▸ | FCER2 | P06734 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634590 | 1.00 | MMP2 (0.58) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634154 | 0.93 | MMP2 (0.62) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4633117 | 0.93 | MMP2 (0.62) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL7840440 | 0.78 | LMNA (0.40) | MMP2MMP1MMP3 | |
| SCHEMBL4635134 | 0.78 | MMP2 (0.76) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4635129 | 0.78 | MMP2 (0.76) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4633254 | 0.77 | MMP2 (0.71) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4633265 | 0.77 | MMP2 (0.71) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4633256 | 0.77 | MMP2 (0.71) | MMP2MMP1MMP12MMP13MMP9 | |
| SCHEMBL4634062 | 0.77 | MMP1 (0.42) | MMP2MMP1MMP12MMP13REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | MMP2 12/4885MMP1 3/4885MMP12 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.